AstraZeneca will buy U.S. biotech firm FibroGen's China unit for about $160 million, in its latest deal to boost its presence ...

AstraZeneca will obtain the full rights to Roxadustat in China, FibroGen said, adding that it will retain the US and other ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

AstraZeneca's SERENA-6 trial shows camizestrant plus a CDK4/6 inhibitor improves progression-free survival in HR-positive, HER2-negative breast cancer.

2025年2月20日，阿斯利康（AstraZeneca）正式宣布将收购珐博进（FibroGen）在中国的业务，交易金额约为1.6亿美元（约11亿元人民币）。这一收购并不仅仅是数字游戏，更是阿斯利康在中国这个潜力巨大的生物制药市场中迈出的重要一步。

2月20日，阿斯利康（AstraZeneca）宣布与珐博进（FibroGen）达成协议，企业将收购珐博进中国，对价约1.6亿美元。根据协议，珐博进将获得8500万美元的企业价值，以及交易交割时珐博进中国持有的约7500万美元现金，总计约1.6亿美元， ...

The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through ...

The company, now based in North Beach, has lost more than $2 billion over 29 years. Its only approved drug, called roxadustat ...

FibroGen sells its China unit to AstraZeneca for $160 million, extending its cash runway into 2027 and advancing its ...

Feb 20 (Reuters) - AstraZeneca (AZN.L), opens new tab will buy longtime partner FibroGen's (FGEN.O), opens new tab China unit for about $160 million to gain rights to its anemia drug in the ...